iBio, Inc. (IBIO) |
|
0.312 0 (0.03%)
|
06-26 23:01 |
|
Open: |
0.311 |
Pre. Close: |
0.3119 |
|
High:
|
0.3267 |
Low:
|
0.311 |
|
Volume:
|
25,728,859 |
Market Cap:
|
68(M) |
|
|
|
|
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.33 - 0.33 |
0.33 - 0.33 |
|
Low:
|
0.31 - 0.31 |
0.31 - 0.31 |
|
Close:
|
0.31 - 0.31 |
0.31 - 0.31 |
|
Technical analysis |
as of: 2022-06-24 4:40:42 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.39 One year: 0.46 |
| Support: |
Support1: 0.26 Support2: 0.21 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.39 |
| Pivot: |
0.28  |
| Moving Average: |
MA(5): 0.31 MA(20): 0.27
MA(100): 0.33  MA(250): 0.68 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 81.1 %D(3): 80.1 |
| RSI: |
RSI(14): 56.3 |
| 52-week: |
High: 1.51 Low: 0.21 |
| Average Vol(K): |
3-Month: 2,980 (K) 10-Days: 4,735 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed below upper band by 27.2%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Biologics Fill and Finish Services Market Size & Analysis By 2022 -2029 -Boehringer Ingelheim, Cambrex, Novasep, Vetter, Lonza, Emergent BioSolutions, Cobra Biologics, Catalent, MabPlex, Polpharma Biologics, Baxter Healthcare Corporation, ABL, In - Indian Defence News
Fri, 24 Jun 2022
iBio Inc. stock rises Friday, still underperforms market - MarketWatch
Thu, 23 Jun 2022
3 Top Penny Stocks to Add to Your July 2022 Watchlist - Miami County Republic
Tue, 21 Jun 2022
Using the power of plants to develop novel biopharmaceuticals - The Science Board
Tue, 21 Jun 2022
Global Novel Coronavirus (COVID-19) Vaccine Market Insight Analysis and Forecast 2022-2029 Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise – Designer Women - Designer Women
Fri, 17 Jun 2022
iBio Inc. stock outperforms competitors on strong trading day - MarketWatch
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
218 (M) |
|
% Held by Insiders
|
2.167e+008 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
11,600 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.038e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.16 |
|
EPS Est Next Year
|
-0.21 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
520.1 |
|
Return on Equity (ttm)
|
-15.9 |
|
Qtrly Rev. Growth
|
2.17e+006 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.08 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-32 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
41.54 |
|
Price to Cash Flow
|
-3.86 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.117e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
